L'Encephale
April 9, 2026
Amel Bouloufa, Sarah Delcourte, Thomas Delannay et al.
Major depressive disorder (MDD) represents a colossal worldwide burden of health, affecting more than 350 million individuals. While traditional antidepressants with mechanisms of action at the serotonin, dopamine, or norepinephrine pathways are routinely prescribed, approximately one-third of patients fail to achieve adequate remission and develop treatment-resistant depression (TRD). This...
BMC Medical Education
April 9, 2026
Nikita Sanati Morel, Dea Siggaard Stenbæk, Johan Lundberg et al.
Major depression is a prevalent condition among patients with life-threatening illnesses, such as cancer, and recent findings suggest that psilocybin may hold promising treatment potential. Contemporary trials of psilocybin generally employ a model that includes psychotherapeutic support consisting of preparation and integration sessions surrounding the dosing. However, there is limited...
Sleep
April 8, 2026
Julia Maruani, Pierre A Geoffroy
2 citations
Nightmares are repeated and lengthy dreams, extremely dysphoric, with clear memory, typically involving life-threatening threats to safety or physical integrity. These nightmares lead to significant distress upon awakening and may substantially impact daytime functioning. Both the experience of these dreams and the sleep disruption produced by the ensuing awakening cause significant impairment...
Frontiers in Psychology
April 7, 2026
Yunn-Wen Lien, Shan-Chuan Teng, Li-Yun Wei
Introduction: Psychological wellbeing among young adults has declined globally, along with rising levels of depression, creating an educational and societal crisis and highlighting the urgent need for school-based mental health interventions. In response, the Body-Mind Axial Awareness (BMAA) method-an embodied body-mind enhancement program rooted in East Asian self-cultivation traditions-was...
Reviews on recent clinical trials
April 7, 2026
Ritika Saun, Aakriti Garg, Mohd Ashif Khan
Most of the Major Depressive Disorder (MDD) patients experience Treatment-Resistant Depression (TRD), wherein standard pharmaceutical and psychological interventions fail to provide adequate symptom relief. This systematic review and meta-analysis investigated the efficacy and safety of intranasal esketamine for rapid symptom relief in adults with TRD. The search strategy adhered to PRISMA...
Frontiers in Psychiatry
April 7, 2026
Ravi Philip Rajkumar
Post-traumatic stress disorder (PTSD) is a chronic mental illness that occurs following exposure to traumatic stressors such as combat, disasters, or assault. It is characterized by a triad of reexperiencing of the trauma, avoidance of triggers for such recollections, and increased vigilance towards threats (1). In 1992, Judith Herman described a variant of PTSD that occurred in persons who had...
Phenomenology and the Cognitive Sciences
April 6, 2026
Thomas Fuchs
1 citation
The feeling of being alive points to an intricate connection between the organic process of life and foundational subjective experience, or between life and experience ( Leben and Erleben ). Based on this premise, I argue that self-experience cannot be understood as an internal mental space or a “self-model” that could be produced and localized in the brain, but rather that it is a...
Medicine
April 3, 2026
Xiaoqian Liu, Hui Chen, Yuna Cheng et al.
Non-small cell lung cancer (NSCLC) patients undergoing surgery and adjuvant chemotherapy often experience debilitating physical and psychological symptoms, including cancer-related fatigue, anxiety, and depression. Mindfulness-based stress reduction (MBSR) has emerged as a complementary intervention to alleviate these burdens and enhance quality of life, but evidence in NSCLC populations...
npj Mental Health Research
April 2, 2026
Peng Tan, Yuqi Wu, Xinrong Chen et al.
3 citations
Depressive disorders are characterized by persistent negative affect, rumination, and impaired emotion regulation, contributing substantially to global disease burden. As recurrent rumination and negative attentional biases are central cognitive mechanisms of depression, interventions targeting these processes have gained increasing attention. Mindfulness-based interventions (MBIs) effectively...
EClinicalMedicine
April 2, 2026
Antony Salamé, Samuel Bulteau, Gabriel Robert et al.
Background Late-life depression with inadequate antidepressant response is a pressing clinical issue with limited proven therapies. Nitrous oxide (N 2 O) may offer a new therapeutic avenue with rapid and safe antidepressant effects in late-life depression with inadequate antidepressant response. Methods We conducted a double-blind, randomised, placebo-controlled, single-dose trial (November...
Yixue xinzhi zazhi
April 2, 2026
Yao Wenzhuang, Zhang Hanyun, Liu Suman et al.
Objective To systematically evaluate the efficacy and safety of Esketamine on postpartum depression (PPD) in cesarean section women.Methods Databases including PubMed, Embase, Web of Science, The Cochrane Library, CBM, CNKI, WanFang and VIP were searched from inception to March 2025 for RCTs investigating the impact of Esketamine on PPD in cesarean section parturients. RevMan 5.4 and Stata 18.0...
Biomolecules
April 2, 2026
Nikola Balic, Gordana Nedic Erjavec, Marcela Konjevod et al.
Major depressive disorder (MDD) is associated with complex metabolic alterations. In this study, we applied a multiplatform metabolomics approach (GC-MS and LC-MS) to characterize the plasma extracellular vesicle (EV) metabolome in healthy controls (N = 50), responsive MDD patients (N = 60), and patients with treatment-resistant depression (TRD; N = 65). Longitudinal analyses were performed...
Drug and Alcohol Dependence
April 1, 2026
Che Liu, Janna Cousijn, Emese Kroon et al.
Although behavioral and epidemiological studies demonstrate high co-morbidity between cannabis use and depression, the underlying neurobiological mechanisms of this relationship remain poorly understood. This study evaluated the interaction between cannabis use and depression on brain resting state functional connectivity using graph theory network properties in 223 individuals who currently...
BMJ Open
April 1, 2026
Maria Niemi, Johannes Michalak, Maria Velana et al.
Introduction Mindfulness-based interventions are widely used, yet concerns about potential negative effects—particularly those related to mindfulness meditation practice—have gained increasing attention. Individuals with difficult-to-treat depression (DTD) represent a population of particular relevance due to heightened vulnerability, but comparative evidence on clinically relevant negative...
Philosophies
April 1, 2026
Patrick Seniuk
Depression is notable for high rates of disability. The medical model typically characterizes depression as a physiological dysfunction or psychological disorder. However, both views fail to appreciate the phenomenology of depressed experience. Drawing on the existential phenomenology of Merleau-Ponty, this article contends that the lived experience of chronic depression is marked by a...
FOCUS: The Journal of Lifelong Learning in Psychiatry
April 1, 2026
Rachel Fremont, Marcella Corwin, Greta Kandel et al.
Over the past 25 years, the field of psychiatry has seen a rapid expansion of ketamine treatment services offered for the off-label management of depression, anxiety, and other psychiatric disorders as well as the U.S. Food and Drug Administration's approval of intranasal esketamine, the S-enantiomer of ketamine, for treatment-resistant depression and suicidal depression. In this review, the...
Scientific Reports
April 1, 2026
David B. Feldman, Shauna L. Shapiro, Diane E Dreher
Mindfulness and hope are both associated with well-being, yet their orientations—present-focused awareness versus future-directed striving—are seemingly at odds. Moreover, limited research addresses them simultaneously. We investigated the relationship between mindfulness and hope, assessing their associations with psychological well-being. A cross-sectional survey of 145 undergraduates (Mage =...
FOCUS: The Journal of Lifelong Learning in Psychiatry
April 1, 2026
Naim Zaki, Li Nancy Chen, Rosanne Lane et al.
Patients with treatment-resistant depression (TRD) have higher rates of relapse and pronounced decreases in daily functioning and health-related quality of life compared to patients with major depressive disorder who are not treatment-resistant, underscoring the need for treatment choices with sustained efficacy and long-term tolerability. Adults with TRD who participated in ≥1 of 6 phase 3...
PLoS Medicine
April 1, 2026
Yifan Li, Vivien Kin Yi Chan, Mark Jit et al.
Treatment-resistant depression (TRD), defined as failure to respond to at least two adequately administered antidepressant (AD) regimens, imposes major clinical and economic burdens. Esketamine nasal spray offers rapid antidepressant clinical effects, yet previous evaluations compared it only with unrealistic comparators such as AD monotherapy. This study assessed the cost-effectiveness of...
JOURNAL OF ADVANCE AND FUTURE RESEARCH
April 1, 2026
Ashish Yadav, Ravina Yadav
Major depressive disorder (MDD) is a complex psychiatric condition associated with alterations in brain neuroplasticity. Brain-derived neurotrophic factor (BDNF), a key regulator of neuronal survival, synaptic plasticity, and neurogenesis, has been widely studied as a biological marker of neuroplasticity in depression. This review and meta-analysis evaluated the relationship between BDNF levels...